What the price tiers include

Three fixed figures cover the full cost of ChondroFiller injection in the UK: £3,000 for one box (a single focal defect), £5,500 for two boxes, and £8,000 for three. There are no separate charges to add on top.

Each tier is structured as an all-in package. Patients pay once and that sum covers the initial consultation, MRI review, real-time ultrasound guidance, the collagen scaffold implant itself, intravenous antibiotic cover on the day, and a six-week follow-up appointment. Because the treatment is delivered as an outpatient ultrasound-guided injection — not an operating-theatre procedure — there are no theatre fees, no anaesthetist's charges, and no hospital admission costs. Specialist centres publishing this pricing, including London Cartilage Clinic on Harley Street, are explicit that the quoted figure is the total figure.

The implant product accounts for the largest share of each tier. ChondroFiller is a CE-marked Class III collagen scaffold manufactured by meidrix biomedicals GmbH in Germany and imported under prescription; its regulatory classification and supply chain are the primary reason the cost sits above standard injectable therapies rather than clinic overhead.

Which tier applies to a given patient depends on defect size and location, both of which require MRI assessment to confirm. A quote given before that imaging has been reviewed is an estimate — the final figure is set only once the scan has been assessed by the treating clinician.

Why ChondroFiller costs more than a standard knee injection

The classification is the key. ChondroFiller carries CE-marked Class III status — the highest risk tier in European medical device regulation — because it does not simply lubricate or cushion the joint. Once injected, the murine-derived Type I collagen scaffold undergoes in-situ gelation and acts as a matrix for the patient's own progenitor cells, which migrate into the scaffold and, over time, produce new cartilage tissue. That process — matrix-induced chondrogenesis — is what places it in the same regulatory category as implantable cardiovascular devices, not in the category of off-the-shelf injectables.

Class III designation obliges meidrix biomedicals GmbH to meet stringent EU manufacturing standards, maintain ongoing post-market clinical surveillance, and satisfy the regulatory requirements attached to importing a prescription-grade biological scaffold into the UK. Those requirements are built into the product's cost before it reaches a clinic. Standard viscosupplementation injections sit in a lower regulatory tier because they work differently — they supplement joint fluid rather than initiating a regenerative process. As noted earlier, the per-dose comparison with those products reflects a structural difference in what each treatment is designed to do. The price premium of ChondroFiller injection, in short, follows from the regulatory burden of the scaffold itself, not from clinic overhead.

NHS funding and private insurance: the realistic picture

For the majority of patients, ChondroFiller injection is a self-funded cost. It is not NHS-commissioned, which means it will not be offered through a GP referral or a standard hospital pathway — private self-pay is the only guaranteed route.

Among the major UK private medical insurers, Bupa and AXA do not currently provide standard coverage for ChondroFiller. Some case-by-case approvals have been reported with Aviva and WPA, billed under CCSD codes W3111 and W8500, but approval rates vary significantly by policy and individual clinical history. Verbal agreement from an insurer is not sufficient — any patient pursuing this route should obtain written pre-authorisation before proceeding. Without that written confirmation, the full cost falls to the patient regardless of what may have been discussed by phone.

On the practical side, the fixed three-tier structure described earlier is relatively uncommon in UK private orthopaedics, where final bills for surgical procedures often depend on theatre time, implant selection, and post-operative complications. Knowing the total cost before the appointment — rather than receiving an itemised invoice afterwards — makes financial planning more straightforward than many of the surgical cartilage repair alternatives.

How the cost compares to surgical knee cartilage repair

Microfracture — historically the first surgical option offered for focal defects — costs £4,000–£6,500 privately in the UK, making it the cheapest surgical route on paper. It requires general or spinal anaesthesia, theatre admission, and a longer rehabilitation period than an outpatient injection. Clinically, its reputation has declined: evidence shows fibrocartilage tissue begins to break down at around two to three years, and repeated marrow stimulation damages the subchondral bone plate in ways that can compromise future repair options. It is rarely the modern first-line choice at specialist cartilage centres.

Scaffold-augmented surgical procedures — AMIC and broader arthroscopic cartilage repair packages — run £7,000–£14,000 at UK private clinics, with London Cartilage Clinic's all-inclusive knee repair starting at £9,800. These procedures still require theatre, a consultant anaesthetist, and a surgical recovery.

Cell-based two-stage procedures escalate sharply. Private ACI or MACI in the UK typically costs £15,000–£25,000 in total, with cell culturing alone reaching £10,000–£17,000 and the total private MACI figure reaching £25,000–£35,000 at specialist centres. Both procedures involve two separate operations and are largely unavailable as private options outside a small number of centres. At the top of the cost ladder, osteochondral allograft replacement (OCA) for larger or post-traumatic defects reaches approximately £28,000 all-inclusive, covering donor tissue, the human-tissue regulatory framework, theatre, anaesthetist, and a twelve-month follow-up.

ChondroFiller injection at £3,000–£8,000 sits at the lower end of this spectrum, comparable in entry price to microfracture, but delivered as an outpatient ultrasound-guided procedure with no theatre booking, no general anaesthetic, and no hospital admission involved. The absence of those components is a factual difference in how the pathway is structured, not a promotional claim. For patients considering the arthroscopic route for larger or more complex defects, that variant begins at approximately £9,500 and should not be conflated with the standard injection tier. Direct RCT-level cost-effectiveness comparisons between ChondroFiller injection and surgical alternatives such as AMIC or microfracture are still emerging, so like-for-like conclusions on value remain preliminary.

Which patients the injection price tier applies to

Knowing which price tier applies begins with a clinical question, not a financial one: does the knee injury fit the treatment's indication?

ChondroFiller injection is designed for focal, contained Grade III/IV articular cartilage defects — areas where cartilage has worn through to the bone but the damage is discrete and surrounded by structurally healthy cartilage borders. Defects up to approximately 6 cm² fall within the treatable range. A single contained lesion at the lower end of that range typically requires one box; larger or multiple focal lesions may require two or three, which is how defect size maps directly to the price tier. That mapping cannot be confirmed without MRI review — a clinic quoting a final figure before seeing the imaging is quoting blind.

Patients with diffuse or advanced osteoarthritis, or bone-on-bone joint disease, fall outside this indication entirely. The scaffold relies on healthy surrounding tissue and intact subchondral architecture; where that environment is absent, a regenerative injectable scaffold is not the appropriate pathway. Those patients would typically be directed toward joint preservation strategies or, where disease is end-stage, replacement.

For patients who do meet the indication, published cohort data show that 70–85% achieve meaningful symptom relief at three to five years. That figure comes from cohort-level evidence rather than large randomised controlled trials comparing ChondroFiller injection directly to surgical alternatives in the knee — a gap in the evidence base that is worth stating plainly, and which means confident cost-effectiveness conclusions versus AMIC or microfracture remain preliminary.

MRI with cartilage-specific sequencing is therefore the practical gateway to the entire pricing conversation: it determines suitability, defect size, box count, and — as a consequence — total cost.

Getting a knee cartilage assessment in Lincolnshire

Any cartilage consultation worth attending should answer three practical questions before a patient commits to a cost: does an MRI confirm a focal, contained defect (and at what grade); does that defect size sit within the one-, two-, or three-box range; and what, specifically, does the recovery timeline look like for that anatomy? Bringing existing imaging — or arranging cartilage-specific MRI sequences before the appointment — is the most efficient way to get concrete answers rather than conditional estimates.

For patients outside London who want that assessment without a GP referral or NHS waiting times, Lincolnshire Knee — part of the MSK Doctors group — offers consultant-led knee assessments at clinics in Sleaford NG34 and Grantham NG31. The Sleaford site includes an Open MRI unit and a dedicated Regeneration Hub. Where MRI analysis is needed, onMRI™ AI-driven cartilage segmentation can assist in confirming defect grade and size — directly relevant to determining which price tier applies.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.